title: Update and New Directions in Therapeutics for Neurological Complications of HIV Infections.
abstract: The pace of therapeutic developments in HIV presents unique challenges to the neurologist caring for patients. Combination antiretroviral therapy (cART) is remarkably effective in suppressing viral replication, preventing, and often even reversing disease progression. Still, not every patient benefits from cART for a variety of reasons, ranging from the cost of therapy and the burden of lifelong daily treatment to side effects and inadequate access to medical care. Treatment failure inevitably leads to disease progression and opportunistic complications. Many of these complications, even those that are treatable, produce permanent neurological disability. With ART, immune recovery itself may paradoxically lead to severe neurological disease; strategies for managing so-called immune reconstitution inflammatory syndrome are beginning to show benefits. Effective cART may nevertheless leave in its wake persistent neurocognitive impairment. Treatments for persistent impairment despite virologic suppression and good immune recovery are being tested but are not yet proven. As we shall see, these treatments target several proposed mechanisms including cerebral small vessel disease, which is highly prevalent in HIV. Most recently, an ambitious initiative has been undertaken to develop interventions to eradicate HIV. This will require elimination of all infectious forms of viral nucleic acid throughout the body. The influence of these interventions on the brain remains to be characterized. Meanwhile, clinical investigators continue to develop antiretroviral treatments that optimize effectiveness, convenience, and tolerability, while minimizing long-term toxicities.
authors.affiliation: University of California San Diego, San Diego, CA, USA. roellis@ucsd.edu.
authors.forename: Ronald
authors.identifier: 0000-0003-4931-752X
authors.initials: R
authors.lastname: Ellis
authors.affiliation: University of California San Diego, San Diego, CA, USA.
authors.forename: Scott L
authors.initials: SL
authors.lastname: Letendre
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D059345:Cerebral Small Vessel Diseases / Q000188:drug therapy / Q000821:virology*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy / Q000821:virology*; D016919:Meningitis, Cryptococcal / Q000821:virology; D019965:Neurocognitive Disorders / Q000188:drug therapy / Q000821:virology*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D018696:Neuroprotective Agents
keywords: AIDS; HIV; Immune reconstitution inflammatory syndrome; antiretroviral; cerebral small vessel disease; eradication; reservoir